One of the primary mechanisms leading GBM progression is angiogenesis, a process that encourages tumour vascularisation, mainly regulated by vascular endothelial growth factor receptor 2 (VEGFR2) and its ligand VEGF-A. The gene discussed is KDR; the disease is glioblastoma.